Coupe N, Schadendorf D, Danson S, et al. PACMEL: A randomised phase 2 study of paclitaxel with or without trametinib or pazopanib in Advanced BRAF wild type melanoma. SMR 2017, abstract SMR05-2.
Anti-PD-1 bij niet-resectabel desmoplastisch melanoom
dec 2025 | Dermato-oncologie, Immuuntherapie